Jasper Therapeutics (JSPR) News Today $2.43 +0.05 (+2.10%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.10 (+4.12%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of "Moderate Buy" by AnalystsSeptember 13 at 3:43 AM | americanbankingnews.comJasper Therapeutics to Present at Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comHealth Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trialAugust 27, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 17, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 16, 2025 | prnewswire.comBTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)August 15, 2025 | theglobeandmail.comJasper Therapeutics price target lowered to $25 from $29 at UBSAugust 15, 2025 | msn.comJasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deJasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)August 14, 2025 | msn.comJasper Therapeutics Reports Promising Q2 2025 ResultsAugust 14, 2025 | msn.comJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 6, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRAugust 1, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 31, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 27, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 22, 2025 | prnewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 20, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 17, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 14, 2025 | globenewswire.comHC Wainwright Issues Positive Estimate for JSPR EarningsJuly 14, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPRJuly 12, 2025 | prnewswire.comJSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJuly 11, 2025 | businesswire.comJasper Therapeutics Announces Corporate Reorganization and Other Cost ...July 11, 2025 | morningstar.comMJasper Therapeutics Announces 50% Workforce Reduction and ... - NasdaqJuly 11, 2025 | nasdaq.comUBS Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)July 9, 2025 | theglobeandmail.comJasper Therapeutics, Inc.: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9, 2025 | finanznachrichten.deJasper Therapeutics Cutting Half of Staff After Study SetbackJuly 9, 2025 | marketwatch.comJasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash RunwayJuly 9, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Given Market Perform Rating at BMO Capital MarketsJuly 8, 2025 | marketbeat.comJasper Therapeutics Inc News (JSPR) - Investing.comJuly 8, 2025 | investing.comCantor Fitzgerald Downgrades Jasper Therapeutics (JSPR)July 8, 2025 | msn.comJasper Therapeutics (NASDAQ:JSPR) Lowered to "Neutral" Rating by Cantor FitzgeraldJuly 7, 2025 | marketbeat.comJasper Therapeutics Shares Fall On Briquilimab Drug Lot ProblemJuly 7, 2025 | benzinga.comJasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous UrticariaJuly 7, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from BrokeragesJune 25, 2025 | marketbeat.comJasper Therapeutics stock maintains buy rating on positive urticaria dataJune 18, 2025 | investing.comJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible UrticariaJune 15, 2025 | nasdaq.comJasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinizedJune 15, 2025 | investing.comJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJune 14, 2025 | globenewswire.comAnalysts Offer Predictions for JSPR FY2026 EarningsJune 10, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressJune 3, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by BrokeragesJune 1, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyMay 29, 2025 | finance.yahoo.comWoodline Partners LP Decreases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 26, 2025 | marketbeat.com Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼0.950.92▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼23▲JSPR Articles Average Week Get the Latest News and Ratings for JSPR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MediWound News FitLife Brands News Caribou Biosciences News biote News Actuate Therapeutics News BioAge Labs News Tevogen Bio News Kyverna Therapeutics News Nuvectis Pharma News Seres Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts